Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate TransMedics Group, Inc. before investing.

In this article, we go over a few key elements for understanding TransMedics Group, Inc.’s stock price such as:

• TransMedics Group, Inc.’s current stock price and volume
• Why TransMedics Group, Inc.’s stock price changed recently
• Upgrades and downgrades for TMDX from analysts
• TMDX’s stock price momentum as measured by its relative strength

About TransMedics Group, Inc. (TMDX)

Before we jump into TransMedics Group, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Want to learn more about TransMedics Group, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about TransMedics Group, Inc..

TransMedics Group, Inc.’s Stock Price as of Market Close

As of May 06, 2026, 9:58 AM, CST, TransMedics Group, Inc.’s stock price was $75.265.

TransMedics Group, Inc. is down 20.72% from its previous closing price of $94.930.

During the last market session, TransMedics Group, Inc.’s stock traded between $72.120 and $78.000. Currently, there are approximately 34.22 million shares outstanding for TransMedics Group, Inc..

TransMedics Group, Inc.’s price-earnings (P/E) ratio is currently at 19.5, which is low compared to the Health Care Equipment & Supplies industry median of 24.4. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

TransMedics Group, Inc. Stock Price History

TransMedics Group, Inc.’s (TMDX) price is currently down 25.32% so far this month.

During the month of May, TransMedics Group, Inc.’s stock price has reached a high of $101.700 and a low of $72.120.

Over the last year, TransMedics Group, Inc. has hit prices as high as $156.000 and as low as $91.010. Year to date, TransMedics Group, Inc.’s stock is down 38.13%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused TransMedics Group, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 05, 2026, there were 0 analysts who downgraded TransMedics Group, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate TransMedics Group, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on TransMedics Group, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

TransMedics Group, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about TransMedics Group, Inc. (TMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of TransMedics Group, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 05, 2026, TransMedics Group, Inc. has a weighted four-quarter relative price strength of -8.86%, which translates to a Momentum Score of 28 and is considered to be Weak.

Want to learn more about how TransMedics Group, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

TransMedics Group, Inc. Stock Price: Bottom Line

As of May 6, 2026, TransMedics Group, Inc.’s stock price is $75.265, which is down 20.72% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like TransMedics Group, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.